TransCode Therapeutics Inc (RNAZ)

[Speculator gipsy]

Crystal ball forest green

[Invest-in-America]

RNAZ: Yep!!! And here comes ONE of them right now in the Post-M, Dude!! And watch that reprobate MM try to stop it!!!!

[MetaMonster]

All eyes on RNAZ Cancer breakthrough

[MetaMonster]

Lots of whales lurking waters Everyone is looking for news

[MetaMonster]

Shorts choking the beast, Shorts Got muscle to keep it down,

[Invest-in-America]

RNAZ: It just hit circa 2.4% DOWN, then we blinked & 1.5% UP!!!

[MetaMonster]

Never know when the volcano will erupt

[Invest-in-America]

RNAZ: Ya never really know; could be Firm Insiders themselves, unloading for petty cash or whatever; or those nasty MM's, just not interested today; but then, all-day-long this has NOT simply crashed hideously either; weird one here, Dude!

[MetaMonster]

Need to push through the 7's

[MetaMonster]

Shorts with muscle keeping this down

[Invest-in-America]

RNAZ: It had popped-UP circa 1.5% green just a few minutes ago; but just can't quite bust that $0.70 resistance point.

[Monksdream]

RNAZ new 52 week low

[MetaMonster]

Time to pull the trigger

[Invest-in-America]

RNAZ: Hey, Dude, its just me & you in the lifeboat now!!! (Yet all day long, it has popped a little GREEN, but just can't hold it. Maybe after NYC LUNCH is over, it might move.)

[MetaMonster]

Let's all hold hands and pray for news

[Invest-in-America]

RNAZ: NOT the most exciting day here, Bro! But I am still PRAYING very hard!!

[DK11]

Someone needs to fix those Rolls Royce engines.

[MetaMonster]

Loading up last of the 60'$ ready

[Invest-in-America]

RNAZ: Hey, Bro, let's get this puppy GOIN'!!!!

[MetaMonster]

Blast off

[Invest-in-America]

RNAZ: Hey, Admiral M-M, we just might be having a little FUN here today, Dude!!

[MetaMonster]

Runway clear rockafella for takeoff

[MetaMonster]

Tripple bottom confirmed, pronto for lift off

[Invest-in-America]

RNAZ: Hang-on, Folks!! Nice surprise coming momentarily!!

[Invest-in-America]

RNAZ: My "BALLS" to the wall??? WHAT??? This stock is drivin' me NUTS!! (Get the pun, Bro?? HA-HAAAA!!)

[Money hunt]

Strap your balls to the walls dude!!! Violent move coming!!! Breakthrough up ahead

[Invest-in-America]

RNAZ: Hope so!!! But still WAITING on this one!! (See ME, below, earlier this evening!!)

[Invest-in-America]

RNAZ: Didn't quite pan-out as expected!! DAMN-IT!!

[MetaMonster]

Load load load rockafella life changing news will hit reality

[MetaMonster]

All aboard from low to high rockafella.. let's roll!!!

[MetaMonster]

New Rolls Royce engines have been installed on rocket cruiser

[MetaMonster]

Trying to load as much as I can bid not getting filled

[Invest-in-America]

RNAZ: Grab them now, or forever hold your wallet??!!

[Money hunt]

The well is dry!! all holding for the glory breakthrough

[Monksdream]

RNAZ new 52 week low

[DK11]

I think the engines blew up on this rocket

[Money hunt]

Shock the world baby!!!! Let’s go RNAZ

[zj3001]

Check out this speaker interview with @MedarovaZdravka as we gear up for the RNAi- Based Therapeutics Summit. pic.twitter.com/ker6yb2aXV

— TransCode Therapeutics (@RNAoncology) January 30, 2024

[MetaMonster]

Jackpot blast off rockafella, can you feel it

[MetaMonster]

More news coming by way of knockout TKO after-hours

[MetaMonster]

News blitz breakthrough up ahead

[MetaMonster]

Don't get fooled by these tycoons, they want your shares

[Gizzer211]

Is that your hunch?

[MetaMonster]

Sound all alarms whales almost ready to explode

[MetaMonster]

Let the whales bottom feed till their stomachs explode

[TheFinalCD]

.777

[MetaMonster]

Boooooooommm blast is imminent

[MetaMonster]

Massive whales accumulating at these levels, bottom feeding

[Money hunt]

Hell yes dude!!!!! TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
January 29 2024 - 08:30AM


Share On Facebook

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced a co-research agreement with Debiopharm, a privately-owned Swiss-based, global biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases. The collaboration will explore combining TransCode’s proprietary TTX delivery platform with Debiopharm’s expertise in targeted drug delivery to co-develop targeted nucleic acid therapeutics for cancer.
TransCode’s TTX platform will serve as a backbone for development of antigen-selective nucleic acid delivery vehicles for targeted cancer therapeutics. TransCode has developed and tested the TTX platform for the delivery of various nucleic acid therapeutics to cancer cells, including small interfering RNAs, antisense oligonucleotides, immunostimulatory oligonucleotides, mRNA, and genome-editing ribonucleoprotein complexes (CRISPR). TransCode’s lead therapeutic candidate, TTX-MC138, designed to use antisense technology to treat metastatic cancer, is being evaluated in an early-stage clinical trial. As part of the collaboration, TransCode will combine its TTX delivery platform with Debiopharm’s proprietary technologies to generate constructs designed to provide targeted mRNA delivery to cancer cells. Under the agreement, these constructs will be tested both in cancer cells and in tumor-bearing animals.

Specializing in the manufacturing and development of oncology and antibiotic therapies, Debiopharm entered this research collaboration to test the development of new targeted nucleic acid delivery modalities. Debiopharm’s ongoing quest towards developing highly innovative drug delivery methods is based on the recognition that novel targeted medicines hold the potential to revolutionize cancer research and treatment by improving precision, efficacy, safety, and the overall therapeutic outcome for cancer patients. The company hopes that future advancements could usher in a new era of more effective and personalized cancer therapies.

Frédéric Lévy, Debiopharm’s Chief Scientific Officer, commented, “We believe that TransCode’s TTX platform has the potential to bring about significant advances in drug delivery for cancer because of its versatility in terms of the payloads it can be used to deliver, including not only a wide array of nucleic acids but also peptides and proteins.”

Zdravka Medarova, TransCode’s Chief Scientific Officer, added, “Debiopharm is a global player in the field of cancer therapeutics, known for the development of standard of care drugs for the treatment of various types of cancer. For TransCode, being able to collaborate with Debiopharm on an innovative project with the potential impact of targeted nucleic acid-based cancer therapeutics, represents a pivotal point for our company.”

[TheFinalCD]

$RNAZ NEWS https://www.globenewswire.com/news-release/2024/01/29/2818904/0/en/TransCode-Therapeutics-and-Debiopharm-Announce-Collaboration-to-Develop-Targeted-Nucleic-Acid-Therapeutics-for-Cancer.html